<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824274</url>
  </required_header>
  <id_info>
    <org_study_id>2012-167-1185</org_study_id>
    <nct_id>NCT04824274</nct_id>
  </id_info>
  <brief_title>TAP Block With Intrathecal Fentanyl vs. Intrathecal Morphine in Cesarean Delivery</brief_title>
  <official_title>Transversus Abdominis Plane Block With Intrathecal Fentanyl Versus Intrathecal Morphine in Cesarean Delivery: A Randomized, Controlled, Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This noninferiority study aims to determine whether transversus abdominis plane (TAP) block&#xD;
      with intrathecal fentanyl could provide a noninferior analgesia compared with intrathecal&#xD;
      morphine after cesarean delivery under spinal anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy mothers scheduled to undergo elective cesarean delivery under spinal anesthesia will&#xD;
      be randomly allocated to receive either TAP block plus intrathecal fentanyl (Group TF) or&#xD;
      intrathecal morphine (Group M).&#xD;
&#xD;
      Primary outcome is pain score with movement at postoperative 24 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score with movement at 24 hours after delivery</measure>
    <time_frame>at 24 hours after delivery</time_frame>
    <description>Pain score with movement at 24hr after delivery, using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intravenous fentanyl consumption</measure>
    <time_frame>at 6, 12, 18, 24, 48 hours after delivery</time_frame>
    <description>cumulative fentanyl consumption via intravenous patient-controlled analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score at rest</measure>
    <time_frame>at 6, 12, 18, 24, 48 hours after delivery</time_frame>
    <description>Pain score at rest using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score with movement</measure>
    <time_frame>at 6, 12, 18, 48 hours after delivery</time_frame>
    <description>Pain score with movement using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first opioid request</measure>
    <time_frame>during hospital stay, an average of 3 days</time_frame>
    <description>time to first intravenous fentanyl administration from delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients requiring rescue analgesics</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>number of patients requiring rescue analgesics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Proportion of patients who experienced nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vomiting</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Proportion of patients who experienced vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pruritus</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Proportion of patients who experienced pruritus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sedation</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Proportion of patients who experienced sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of respiratory depression</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Proportion of patients who experienced respiratory depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea severity</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Nausea severity using 4-point scale with 0=none, 1=mild, 2=moderate, or 3=severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus severity</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Pruritus severity using 4-point scale with 0=none, 1=mild, 2=moderate, or 3=severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction for overall postoperative managements using 11-point scale (0=totally unsatisfied; 10=totally satisfied)</measure>
    <time_frame>During the first 48 hour-period after delivery</time_frame>
    <description>Patient satisfaction score for overall postoperative pain managements using 11-point scale (0=totally unsatisfied; 10=totally satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>From admission to hospital discharge, an average of 3 days</time_frame>
    <description>Hospital length of stay (day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Score</measure>
    <time_frame>at 1 minute, at 5 minutes</time_frame>
    <description>Apgar Score of fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical arterial pH</measure>
    <time_frame>immediately after delivery</time_frame>
    <description>Umbilical arterial pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical arterial PO2</measure>
    <time_frame>immediately after delivery</time_frame>
    <description>Umbilical arterial PO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical arterial PCO2</measure>
    <time_frame>immediately after delivery</time_frame>
    <description>Umbilical arterial PCO2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Transversus abdominis plane block and intrathecal fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.</description>
    <arm_group_label>Transversus abdominis plane block and intrathecal fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
    <description>Morphine 75 mcg will be injected intrathecally during spinal anesthesia.</description>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <other_name>Morphine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus abdominis plane block</intervention_name>
    <description>Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.</description>
    <arm_group_label>Transversus abdominis plane block and intrathecal fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham block</intervention_name>
    <description>Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.</description>
    <arm_group_label>Intrathecal morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult full-term parturients scheduled to undergo elective cesarean delivery under&#xD;
             spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to spinal anesthesia&#xD;
&#xD;
          -  Any chronic pain unrelated pregnancy&#xD;
&#xD;
          -  current opioid medication use&#xD;
&#xD;
          -  BMI more than 40 kg m-2&#xD;
&#xD;
          -  History of drug allergy or hypersensitivity to fentanyl, morphine, ropivacaine,&#xD;
             acetaminophen, NSAIDs, bupivacaine, ramosetron, ondansetron, nalbuphine, Naloxone,&#xD;
             metoclopramide&#xD;
&#xD;
          -  infection of abdominal wall&#xD;
&#xD;
          -  Pregnancy-induced hypertension&#xD;
&#xD;
          -  known cardiovascular disease&#xD;
&#xD;
          -  Known fetal anomaly&#xD;
&#xD;
          -  Any sign of onset of labor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Tae Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun-Kyung Park, MD, PhD</last_name>
    <phone>+821024505924</phone>
    <email>mayskpark@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jin-Tae Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Tae Kim, MD. PhD</last_name>
      <phone>82-2-2072-3664</phone>
      <email>jintae73@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Cole J, Hughey S, Longwell J. Transversus abdominis plane block and intrathecal morphine use in cesarean section: a retrospective review. Reg Anesth Pain Med. 2019 Sep 13. pii: rapm-2019-100483. doi: 10.1136/rapm-2019-100483. [Epub ahead of print]</citation>
    <PMID>31519816</PMID>
  </reference>
  <reference>
    <citation>Patel SD, Sharawi N, Sultan P. Local anaesthetic techniques for post-caesarean delivery analgesia. Int J Obstet Anesth. 2019 Nov;40:62-77. doi: 10.1016/j.ijoa.2019.06.002. Epub 2019 Jun 8. Review.</citation>
    <PMID>31262444</PMID>
  </reference>
  <reference>
    <citation>Kwikiriza A, Kiwanuka JK, Firth PG, Hoeft MA, Modest VE, Ttendo SS. The analgesic effects of intrathecal morphine in comparison with ultrasound-guided transversus abdominis plane block after caesarean section: a randomised controlled trial at a Ugandan regional referral hospital. Anaesthesia. 2019 Feb;74(2):167-173. doi: 10.1111/anae.14467. Epub 2018 Nov 1.</citation>
    <PMID>30383289</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>transversus abdominis plane block</keyword>
  <keyword>morphine</keyword>
  <keyword>fentanyl</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>cesarean section</keyword>
  <keyword>postoperative analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

